Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer

Equality Impact Assessment (Guidance development) (PDF 144 KB)

Committee papers TA416 committee papers (PDF 12.42 MB)

Committee papers TA416 committee papers (PDF 3.51 MB)

Register of interests (PDF 345 KB)

Final draft guidance

Final appraisal document (PDF 213 KB)

Public committee slides (PDF 822 KB)

Committee papers (PDF 5.78 MB)

Final stakeholder list (PDF 100 KB)

Final scope (PDF 120 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 126 KB)